CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021
This report can be delivered to the clients within 48-72 Hours
DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
CAR T-Cell Therapy for Multiple Myeloma: Overview
Multiple Myeloma also known as Kahler’s disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn’t cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
“CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Chapters
This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs
PHE 885: Novartis Pharmaceuticals
Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the treatment of multiple myeloma.
JNJ-68284528: Janssen Biotech
Janssen’s drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status.
Further product details are provided in the report……..
CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in CAR T-Cell Therapy for Multiple Myeloma
There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the mid to advanced stage and in early stage, i.e. phase I include, Novartis Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CAR T-Cell Therapy for Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.
CAR T-Cell Therapy for Multiple Myeloma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
CAR T-Cell Therapy for Multiple Myeloma: Overview
Multiple Myeloma also known as Kahler’s disease is a type of blood cancer that affects plasma cells a subtype of white blood cells. Plasma cells are antibody generating cells. When an individual suffers from multiple myeloma these plasma cells produce immunoglobins in excess which damage the other organs of the body. Multiple Myeloma is usually rare and based on the effect on the body it is categorized into two: an indolent myeloma, usually develops slowly and doesn’t cause bone tumors. There is only slight increase in (monoclonal) M plasma cells and protein, and a solitary plasmacytoma, typically form tumors in bone. Multiple myeloma is not curable and treatment can only slow down the cancer progression. However, CAR T-Cell therapy is a novel therapy which make use of genetically engineered T cell to make chimeric antigen protein which in turn identify the target protein on cancerous cells and kill them. CAR T-cell treatments for multiple myeloma target a protein called B-cell maturation antigen (BCMA), present on the surface of myeloma cells but not healthy cells.
“CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Chapters
This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs
PHE 885: Novartis Pharmaceuticals
Novartis drug candidate, PHE 885, is in its phase I trials. The study is to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR). The drug is in the development for the treatment of multiple myeloma.
JNJ-68284528: Janssen Biotech
Janssen’s drug JNJ-68284528 is currently being evaluated for the treatment of CAR T-Cell Therapy for Multiple Myeloma. The drug is in pre-registration and from the class CAR-T cell therapies. The drug has been designated with orphan drug status.
Further product details are provided in the report……..
CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment
This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in CAR T-Cell Therapy for Multiple Myeloma
There are approx. 5+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the mid to advanced stage and in early stage, i.e. phase I include, Novartis Pharmaceuticals and others.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Molecule Type
- Small molecules
- Natural metabolites
- Monoclonal antibodies
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
CAR T-Cell Therapy for Multiple Myeloma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.
CAR T-Cell Therapy for Multiple Myeloma Report Insights
- CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing CAR T-Cell Therapy for Multiple Myeloma drugs?
- How many CAR T-Cell Therapy for Multiple Myeloma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Novartis
- Janssen Biotech
- Yake Biotech
- Celgene Corporation
- PHE 885
- JNJ-68284528
- APRIL CAR-T cells
- bb 2121
Introduction
Executive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CAR T-Cell Therapy for Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CAR T-Cell Therapy for Multiple Myeloma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I)
Comparative Analysis
PHE 885: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical Stage
Comparative Analysis
JNJ-68284528: Janssen Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
CAR T-Cell Therapy for Multiple Myeloma Key Companies
Appendix
Executive Summary
CAR T-Cell Therapy for Multiple Myeloma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
CAR T-Cell Therapy for Multiple Myeloma – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
CAR T-Cell Therapy for Multiple Myeloma companies’ collaborations, Licensing, Acquisition -Deal Value Trends
CAR T-Cell Therapy for Multiple Myeloma Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Early Stage Products (Phase I)
Comparative Analysis
PHE 885: Novartis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical Stage
Comparative Analysis
JNJ-68284528: Janssen Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
CAR T-Cell Therapy for Multiple Myeloma Key Companies
CAR T-Cell Therapy for Multiple Myeloma Key Products
CAR T-Cell Therapy for Multiple Myeloma- Unmet Needs
CAR T-Cell Therapy for Multiple Myeloma- Market Drivers and Barriers
CAR T-Cell Therapy for Multiple Myeloma- Future Perspectives and Conclusion
CAR T-Cell Therapy for Multiple Myeloma Analyst Views
CAR T-Cell Therapy for Multiple Myeloma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for CAR T-Cell Therapy for Multiple Myeloma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
